Cortical glucose metabolism in Parkinson's disease without dementia
- PMID: 7936057
- DOI: 10.1016/0197-4580(94)90028-0
Cortical glucose metabolism in Parkinson's disease without dementia
Abstract
There have been several reports of decreased regional cerebral metabolic rates for glucose (rCMRglc) in Parkinson's disease (PD), although others find no differences between PD patients and controls. Differences in the cognitive status of the PD patients may account for some of these inconsistencies. We report the results of a PET study using 18F-fluorodeoxyglucose (FDG) to measure rCMRglc in eight nondemented PD patients, six of whom were receiving dopaminergic medications, and eight age-matched control subjects. We scanned one tomographic level through the temporal lobes that included both temporal neocortex and mesial temporal cortex, and one tomographic level through the basal ganglia that included frontal and parietal cortex. Previously determined rate constants and an operational equation were used to determine rCMRglc. On average, rCMRglc values were 23% below control values for all regions studied, with the greatest differences in posterior brain regions (visual association cortex, primary visual cortex, and parietal cortex) and thalamus. These results indicate that PD patients may show neocortical hypometabolism, especially in posterior brain regions, in the absence of any demonstrable cognitive deficits.
Similar articles
-
The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease.Brain Res. 1993 Dec 3;629(2):189-98. doi: 10.1016/0006-8993(93)91320-r. Brain Res. 1993. PMID: 8111623
-
Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET.Mov Disord. 2001 Nov;16(6):1014-22. doi: 10.1002/mds.1212. Mov Disord. 2001. PMID: 11748732
-
[Cerebral glucose metabolism in Parkinson's disease with dementia].Zhonghua Yi Xue Za Zhi. 2008 Oct 14;88(37):2623-8. Zhonghua Yi Xue Za Zhi. 2008. PMID: 19080710 Chinese.
-
[18F-fluorodeoxyglucose positron emission tomography in Parkinson's disease].Nihon Rinsho. 1997 Jan;55(1):222-6. Nihon Rinsho. 1997. PMID: 9014454 Review. Japanese.
-
Positron emission tomography in patients with clinically diagnosed Alzheimer's disease.CMAJ. 1986 Mar 15;134(6):597-607. CMAJ. 1986. PMID: 3512063 Free PMC article. Review.
Cited by
-
Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson's disease: comparison of mice strains and dose regimens.Metab Brain Dis. 2021 Dec;36(8):2343-2357. doi: 10.1007/s11011-021-00840-2. Epub 2021 Oct 14. Metab Brain Dis. 2021. PMID: 34648126
-
Association between gene expression and functional-metabolic architecture in Parkinson's disease.Hum Brain Mapp. 2023 Nov;44(16):5387-5401. doi: 10.1002/hbm.26443. Epub 2023 Aug 22. Hum Brain Mapp. 2023. PMID: 37605831 Free PMC article.
-
Visual symptoms in Parkinson's disease.Parkinsons Dis. 2011;2011:908306. doi: 10.4061/2011/908306. Epub 2011 May 25. Parkinsons Dis. 2011. PMID: 21687773 Free PMC article.
-
Visual dysfunction in Parkinson's disease.Brain. 2016 Nov 1;139(11):2827-2843. doi: 10.1093/brain/aww175. Brain. 2016. PMID: 27412389 Free PMC article. Review.
-
The pentose phosphate pathway regulates chronic neuroinflammation and dopaminergic neurodegeneration.J Neuroinflammation. 2019 Dec 5;16(1):255. doi: 10.1186/s12974-019-1659-1. J Neuroinflammation. 2019. PMID: 31805953 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical